EMA has recommended granting a marketing authorisation in the European Union for Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in adolescents from 12 years of age weighing at least 40 kg. Plaque psoriasis is a common chronic inflammatory skin disease affecting around 1% to 4% of adults and up to 1% of children worldwide. The condition can have a significant impact on people’s quality of life, causing both physical and psychological discomfort. Although a range of treatments is available, there remains a need for effective, safe and convenient treatments for this condition. Many patients do not achieve adequate control of their symptoms, and the effects of treatment can wane over time. Some
EMA - European Medicines Agency · March 30, 2023
Marketing authorisation recommended for Icotyde (icotrokinra) for plaque psoriasis
Original title: First oral medicine targeting interleukin-23 receptor recommended for plaque psoriasis
EMA recommended marketing authorisation for Icotyde (icotrokinra), an oral interleukin-23 receptor inhibitor, for moderate-to-severe plaque psoriasis in adults and adolescents aged 12+ weighing ≥40 kg.
Published by EMA - European Medicines Agency. HealthSignal links to the original document; the summary above is extracted from the source text.